How do patients choose between obesity medications: A thematic analysis
-
Mondoh A, Craig H, Crotty M, Contreras F, le Roux CW.
How do patients choose between obesity medications: A thematic analysis Obes Pillars
Publication Category: Medications
GPs’ perspectives on GLP-1RAs for obesity management: a qualitative study in England
-
Keating S, Wild C, Scragg J, Dixon S, Treadwell JS, Hinton L, Jebb S.
GPs’ perspectives on GLP-1RAs for obesity management: a qualitative study in England Br J Gen Pract
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity
-
Cohen RV, Prager G, le Roux CW, Lingvay I, Salminen P.
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity Lancet Diabetes Endocrinol
Digital Clinicians Performing Obesity Medication Self-Injection Education: Feasibility Randomized Controlled Trial
-
Coleman S, Lynch C, Worlikar H, Kelly E, Loveys K, Simpkin AJ, Walsh JC, Broadbent E, Finucane FM, O' Keeffe D.
Digital Clinicians Performing Obesity Medication Self-Injection Education: Feasibility Randomized Controlled Trial JMIR Diabetes
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
-
Pack A, Grunstein R, Mokhlesi B, Ryan S, Schwab R, Gozal D.
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)? Sleep
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
-
Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP; SURMOUNT-5 Trial Investigators.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity N Engl J Med
Glucagon-like peptide 1 (GLP-1) receptor agonists’ use during pregnancy: Safety data from regulatory clinical trials
-
Parker CH, Slattery C, Brennan DJ, le Roux CW.
Glucagon-like peptide 1 (GLP-1) receptor agonists’ use during pregnancy: Safety data from regulatory clinical trials Diabetes Obes Metab
Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes
-
Al-Najim W, Raposo A, BinMowyna MN, le Roux CW.
Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes Nutrients
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
- Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, Lingvay I, Lyndgaard CB, Rosenstock J, Pedersen SD; REDEFINE 2 Study Group. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes N Engl J Med
Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss
-
Heald AH, Reynolds G, Nash I, Boyle O, Daly C, Longson D, O'Shea D, Ingram J, Holt R, Firth J, Stedman M, Syed A, de Hert M.
Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss Adv Ther